期刊文献+

FDA批准Synribo治疗成人慢性粒细胞性白血病 被引量:1

下载PDF
导出
摘要 2012年10月26日,Teva公司的Synribo通过快速审批获美国FDA批准,用于酪氨酸激酶抑制剂治疗后依然进展的成人慢性髓细胞性白血病(CML)患者的治疗。该药为首个用于CML治疗的蛋白质合成抑制剂,同时获"孤儿药"资格认证。
出处 《齐鲁药事》 2012年第12期691-691,共1页 qilu pharmaceutical affairs
  • 相关文献

同被引文献19

  • 1景莉,王秦,李晓明.丹参酮Ⅱ_A对急性早幼粒细胞白血病作用的研究进展[J].中国药房,2006,17(12):942-943. 被引量:8
  • 2王振义.急性早幼粒细胞白血病的维甲酸治疗[M]∥陆道培.白血病治疗学.北京:科学出版社.1992:152.
  • 3Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable[J]. Blood, 2008, 111 (5) : 2 505.
  • 4Stein E, McMahon B, Kwaan H, et al. The coagulopa- thy of acute promyelocytic leukaemia revisited[J]. Best Pract Res Clin Haemat, 2009,22( 1 ) : 153.
  • 5Fenanx P, Chastang C, Chevret S, et al. A randomized comparison of all-trans retinoic acid(ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promy- elocytic leukemia.The European APL Group[J]. Blood, 1999,94(4) : 1 192.
  • 6Kantarijian HM, Talpaz M, Santini V, et al. Homohar- ringtonine: history, current research, and future direction [J]. Cancer, 2001,92(6) : 1 591.
  • 7Huang CL, Deng ML, Guo F J, et al. A study on the in- duction of differentiation of human leukemia cells by har- ringtonine combined with cytarabine[J]. Leukemia, 1988, 2(8):518.
  • 8Boyd AW, Sullivan JR. Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differ- entiation induced by the antileukemic drug harringtonine [J]. Blood, 1984,63 (2) : 384.
  • 9Higgins JPT, Grenn S. Cochrane Handbook for Systemat- ic Reviews of Interventions Version 5.1.0 [EB/OL]. [2013- 10-01]. http ://www.cochrane-handbook.org.
  • 10Zhou DC, Zittoun R, Marie JP, et al. Homoharringto- nine: an effective new natural product in cancer chemo- therapy[J]. Bull Cancer, 1995,82 (12):987.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部